NEWS COMMENTARY

Pear Therapeutics goes public in SPAC deal

Published:
June 30, 2021
Last Updated:
June 30, 2021
Services:
CPG More...
Priorities:
“Better-for-You” Transformation More...
Activities:
Acquisition More...
by Danielle Bradnan
Very important

The $1.6 billion deal will make Pear Therapeutics (now Pear Holdings Corp.) one of the first digital therapeutics companies to go public. The SPAC merger will allow Pear to go on with commercialization and expansion plans that have struggled since the relationship with Novartis Pharmaceuticals became strained. Going public will likely increase the company's funding opportunities beyond the more traditional investments made in digital therapeutics by pharma players and will improve its image in the healthcare world. As a relatively new market player heralding a technology that only received FDA approval in 2018, Pear needs as much image support as possible – and this merger will help it on both the funding potential and legitimacy fronts.

For the original news article, click here .


Further Reading

Seed Health raises $40 million Series A for its synbiotic product

News Commentary | May 05, 2021

This Series A round was led by The Craftory, Artis Ventures, and Gisev. With this funding, the company is looking to expand its consumer health supplement globally as well as focus on clinical research and its digital health unit, following its recent acquisition of Auggi. Seed's therapeutic arm has... Not part of subscription

G2 Venture closes $500 million fund targeting climate change-mitigating technologies but still lacks deep decarbonization startups

News Commentary | July 08, 2021

Last month, G2V announced the close of a $500 million fund following its inaugural $350 million fund in 2017. Continuing with its original investment thesis, G2V will target companies active in the energy, manufacturing, logistics, transportation, and agriculture industries, with an emphasis on "... Not part of subscription

Akili Interactive is going public, expected to net USD 412 million and open up investment opportunities

News Commentary | February 01, 2022

The company will be going public through a special purpose acquisition company known as Social Capital Suvretta Holdings Corp. Akili Interactive will use the expected cash proceeds to support the rollout of their U.S. FDA‑approved pediatric ADHD therapeutic, EndeavorRx. With EndeavorRX, Akili is ... Not part of subscription